In this report, we developed novel chlorin/arylaminoquinazoline conjugates for targeted photodynamic therapy of cancer. The synthesized photosensitizers consisted of chlorin-e6 metallocomplexes (Zn, In, or Pd) conjugated with arylaminoquinazoline ligands with high affinity for EGFR receptors. Through the incorporation of cationic moieties, we successfully prepared water-soluble conjugated drugs suitable for intravenous administration. Comprehensive SAR studies were conducted to evaluate the influence of structural features on the photodynamic activity of these conjugates. Additionally, the selectivity and antitumor properties of the conjugates were investigated in EGFR-expressing A431 human tumor cell line in vitro. Among the tested molecules, the In-containing conjugate effectively inhibited tumor cell proliferation at nanomolar concentrations, a rare property for conventional photosensitizers. In in vivo experiments, the conjugates rapidly accumulated at the tumor site in nude mice bearing A431 xenograft tumors. Subsequent distribution analysis among different tissues was carried out using fluorescence imaging and elemental analysis. Finally, we demonstrated that the most promising In-containing conjugate was capable of inhibiting xenograft tumor growth in mice through combinational therapy.
Latest studies highlight boron-dipyrromethene (BODIPY) with meso-methyl moiety as a promising photoremovable protecting group due to its activation within the phototherapeutic window. While BODIPYs inherently generate ROS and act as photosensitizers, few studies have explored combining their photouncaging capability with photodynamic therapy (PDT). Herein, we developed novel meso-methyl-BODIPY conjugates of the DNA alkylator Boc-seco-CBI and the multikinase inhibitor cabozantinib derivative, activated by green or red light. To enhance photodecaging efficiency of conjugates, heavy atoms (Br, I) were introduced, and the boron atom was alkylated. The synthesized compounds were characterized for key photophysical and photochemical properties, including quantum yields of singlet oxygen generation, fluorescence, photolysis and cytostatic release. It was shown, that green-light irradiation of halogenated Boc-seco-CBI conjugates enabled rapid cytostatic release (<1 min), though with modest drug yields due to competing photodegradation. However, efficient uncaging of the cytostatic from the BODIPY-cabozantinib conjugate was achieved only after extended photoirradiation (~80 min) with red light. In vitro evaluation using tumor (MDA-MB-231, A431) and normal (HEK293) cell lines with various EGFR/c-Met expression demonstrated that the BODIPY-cabozantinib conjugate exhibited predominant photosensitizing effects, with minimal cytostatic contribution. During this study, we encountered significant synthetic challenges in developing red-light-absorbing conjugates, coupled with their photodegradation under prolonged irradiation. Our observations reveal key considerations for developing conjugates based on meso-methyl-BODIPY that combine PDT with light-controlled drug release toward antitumor therapy.